Mitani, Seiichiro http://orcid.org/0000-0003-0033-8741
Kato, Ken
Daiko, Hiroyuki
Ito, Yoshinori
Nozaki, Isao
Kojima, Takashi
Yano, Masahiko
Nakagawa, Satoru
Ueno, Masaki
Watanabe, Masaya
Tsunoda, Shigeru
Abe, Tetsuya
Kadowaki, Shigenori
Kadota, Tomohiro
Sasaki, Keita
Machida, Ryunosuke
Kitagawa, Yuko
Funding for this research was provided by:
National Cancer Center Research and Development Fund (2020-J-3)
Article History
Received: 18 September 2021
Accepted: 26 February 2022
First Online: 11 May 2022
Declarations
:
: Seiichiro Mitani reports research grants from Taiho Pharmaceutical Co. Ken Kato reports research grants from MSD, Ono Pharmaceutical Co., Merck Serono, Bayer, Beigene, Oncologys Biopharma, Chugai Pharmaceutical Co., and Shionogi. Takashi Kojima reports research grants from Ono Pharmaceutical Co., MSD, Amgen Astellas BioPharma, Chugai Pharmaceutical Co., Shionogi, Parexel, and Taiho Pharmaceutical Co. Yuko Kitagawa is a member of endowed chair from Taiho Pharmaceutical Co., and Chugai Pharmaceutical Co. and reports honorariums from ASAHI KASEI PHARMA Corporation, Taiho Pharmaceutical Co., Ono Pharmaceutical Co., and Chugai Pharmaceutical Co., scholarship grants from Chugai Pharmaceutical Co., Taiho Pharmaceutical Co., Yakult Honsha, ASAHI KASEI PHARMA Corporation, Ohtsuka Pharmaceutical Co., Ltd., and Ono Pharmaceutical Co., trips and other gifts unrelated to research, education, or health care from Ono Pharmaceutical Co. and Bristol Myers Squibb. All remaining authors have declared no conflicts of interest.